

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2605099

| | |
|--|------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| CANCER RESEARCH VENTURES LIMITED | 10/31/2002 |
| RECEIVING PARTY DATA | |
| Name: | CANCER RESEARCH TECHNOLOGY LIMITED |
| Street Address: | 61 LINCOLN'S INN FIELDS |
| City: | LONDON |
| State/Country: | UNITED KINGDOM |
| Postal Code: | WC2A 3PX |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 13894843 |
| CORRESPONDENCE DATA | |
| Fax Number: | (703)816-4100 |
| Phone: | 7038164000 |
| Email: | pp@nixonvan.com |
| <i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i> | |
| Correspondent Name: | B. J. SADOFF |
| Address Line 1: | 901 NORTH GLEBE ROAD, 11TH FLOOR |
| Address Line 4: | ARLINGTON, VIRGINIA 22203 |
| ATTORNEY DOCKET NUMBER: | BJS-620-575 |
| NAME OF SUBMITTER: | B. J. SADOFF |
| Signature: | /B. J. Sadoff/ |
| Date: | 11/06/2013 |
| Total Attachments: 18 | |

502559395

PATENT
 REEL: 031552 FRAME: 0964

OP \$40.00 13894843

source=5-Assignment_from_CRVL-to-CRTL#page1.tif
source=5-Assignment_from_CRVL-to-CRTL#page2.tif
source=5-Assignment_from_CRVL-to-CRTL#page3.tif
source=5-Assignment_from_CRVL-to-CRTL#page4.tif
source=5-Assignment_from_CRVL-to-CRTL#page5.tif
source=5-Assignment_from_CRVL-to-CRTL#page6.tif
source=5-Assignment_from_CRVL-to-CRTL#page7.tif
source=5-Assignment_from_CRVL-to-CRTL#page8.tif
source=5-Assignment_from_CRVL-to-CRTL#page9.tif
source=5-Assignment_from_CRVL-to-CRTL#page10.tif
source=5-Assignment_from_CRVL-to-CRTL#page11.tif
source=5-Assignment_from_CRVL-to-CRTL#page12.tif
source=5-Assignment_from_CRVL-to-CRTL#page13.tif
source=5-Assignment_from_CRVL-to-CRTL#page14.tif
source=5-Assignment_from_CRVL-to-CRTL#page15.tif
source=5-Assignment_from_CRVL-to-CRTL#page16.tif
source=5-Assignment_from_CRVL-to-CRTL#page17.tif
source=5-Assignment_from_CRVL-to-CRTL#page18.tif

DATED 31 OCTOBER 2002


CANCER RESEARCH VENTURES LIMITED

- and -

CANCER RESEARCH TECHNOLOGY LIMITED

INTELLECTUAL PROPERTY ASSIGNMENT

I certify that this is a true copy of the original document.


C.D.G. Pickering
Solicitor of the Supreme Court of England and Wales
(Roll number 199245)

THIS DEED OF ASSIGNMENT is made the 31st day of OCTOBER 2002

BETWEEN:

- (1) **CANCER RESEARCH VENTURES LIMITED** a company registered in England (registered number 3521378) whose registered office is situated at 5 Alfred Place, London WC1E 7EB (the "Assignor"); and
- (2) **CANCER RESEARCH TECHNOLOGY LIMITED (formerly known as CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED)** a company registered in England (registered number 1626049) whose registered office is situated at 61 Lincoln's Inn Fields, London WC2A 3PX (the "Assignee")

WHEREAS:

In accordance with an agreement 30 September 2002 made between the Assignor and the Assignee, it was agreed that all of the Assignor's right, title and interest in and to the Assignor Intellectual Property (as defined below) shall be assigned to Assignee, subject to and with the benefit of any encumbrances (including any licence or other agreements) relating to such Assignor Intellectual Property, on the following terms and conditions.

NOW THIS DEED WITNESSES as follows:

I. DEFINITIONS AND INTERPRETATION

- 1.1 In this Assignment and in the Schedule to this Agreement the following words and phrases shall have the following meanings unless the context requires otherwise:

"Assignment" means this deed of assignment and any and all schedules, appendices and other addenda to it as may be varied from time to time in accordance with the provisions of this assignment.

"Assignor Intellectual Property" means the Assignor Patent Rights, but excluding any right that is by way of or in the nature of a licence.

"Assignor Patent Rights" means the patents and patent application particulars of which are set out in Schedule 1 together with any Patent Rights which claim priority or are derived therefrom or which claim the same subject matter as such patents and patent applications.

"Parties" means the Assignors and Assignee and "Party" shall be construed accordingly.

"Patent Rights" means any patent applications, patents, author certificates, inventor certificates, utility certificates and all foreign counterparts of them and includes all divisions, renewals, continuations, continuations-in-

part, extensions, reissues, substitutions, confirmations, registrations, revalidations and additions of or to them, as well as any SPC, or like form of protection.

"SPC"

means a right based on a patent pursuant to which the holder of the right is entitled to exclude third parties from using, making, having made, selling or otherwise disposing or offering to dispose of, importing or keeping the product to which the right relates, such as Supplementary Protection Certificates in Europe, and any similar right anywhere in the world.

1.2 The headings used in this Assignment shall not affect its interpretation except in the Schedule.

2. ASSIGNMENT

2.1 The Assignor HEREBY ASSIGNS to the Assignee absolutely, subject to and with the benefit of any and all encumbrances (including without limitation any licence or other agreements), all of its right, title and interest throughout the world in and to:

2.1.1 the Assignor Intellectual Property (including all right, title and interest in Canada and the United States of America and all other countries of the world);

2.1.2 all rights and powers arising or accrued from the Assignor Intellectual Property including the right to recover and take all such proceedings as may be necessary for the recovery of damages and/or other remedies in respect of all infringements whether committed before or after the date of this Assignment and to have the benefit of any remedy obtained on any infringement or alleged infringement before the date of this Assignment; and

2.1.3 the right to apply for, prosecute and to obtain Patent Rights in any part of the world (including but not limited to Canada and the United States) in respect of the Assignor Patent Rights and to claim priority from the date of any application embodied in the Assignor Patent Rights, with the intent that the grant of any patents or similar protection shall be in the name of and vest in Assignee.

2.2 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the invention described in the Assignor Patent Rights in the name of Assignee or its successors or assigns in accordance with this Assignment.

3. FURTHER ASSURANCE

3.1 At the request and cost of the Assignee and without unreasonable delay, the Assignor shall sign, execute, make and do all such further deeds, documents, acts and things as Assignee may reasonably require to give effect to this Assignment and to allow Assignee to enjoy the full benefit of the rights hereby assigned.

4. GENERAL

- 4.1 Failure by any of the parties to enforce at any time or for any period any one or more of the terms or conditions of this Assignment shall not be a waiver of them or the rights at any time subsequently to enforce all terms and conditions of this Assignment.
- 4.2 This Assignment shall be binding upon the Assignors' successors and shall enure to the benefit of any successors and/or assigns of Assignee and references to a Party shall include reference to its successors and/or assigns.

5. GOVERNING LAW AND JURISDICTION

- 5.1 All matters relating to this Assignment shall be governed by English law and the Parties submit to the exclusive jurisdiction of the courts of England and Wales.

SCHEDULE 1

Assignor Patent Rights

| PROJECT | PATENT TITLE | CRY FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|------------|---|-----------------------------|---------|---|-------------|----------------------|
| Regent 4 | Improvements Relating to Cancer Therapy | 016/0005 - Mewburn Ellis | US | 09/898461 (Publication no.: US 2002 - 0090709-A1) | 5/7/01 | Priority Application |
| Regent 5 | Improved Antibodies | 016/0007 - JA Kemp & Co US | US | 60/392,354 | 1/7/02 | Priority |
| Bernards 1 | Expression System | 037/0018 - Kilburn & Strode | UK | | | Priority |
| | | | UK | 0130955.8 | 24/12/01 | Priority |
| | | | UK | 0218556.9 | 9/8/02 | Application |
| | | | US | 60/377482 | 2/5/02 | Application |
| | | | US | TBC | 9/8/02 | Application |
| Blow 1 | Assay Methods | 051/0005 - Mewburn Ellis | UK | 0209508.1 | 25/4/02 | Priority |
| Cooper 2 | HEB01 | 008/0038 - Mewburn Ellis | UK | 0127344.0 | 14/1/01 | Priority |

CIDG/005 / 6012 A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|-----------|---|------------------------|---------|--|--------------------------|-------------|
| Darling 2 | Materials & methods relating to increasing Retroviral Titre | 060/0006 - Mowburn EHS | UK | 0096198 | 18/4/00 | Nationals |
| | | | UK | 0137316 | 14/2/01 | Priority |
| | | | PCT | PCT/GB01/01261 | 22/3/01 | PCT |
| | | | AU | TBC | 18/11/02 | Application |
| | | | CA | TBC | 18/10/02 | Application |
| | | | CN | TBC | 18/10/02 | Application |
| | | | EP | TBC | 18/11/02 | Application |
| | | | HK | TBC | " | Application |
| | | | INDIA | TBC | 18/11/02 | Application |
| | | | JP | TBC | 18/10/02 | Application |
| | | | KR | TBC | 18/11/02 | Application |
| | | | NZ | TBC | 18/11/02 | Application |
| | | | SG | TBC | 18/10/02 | Application |
| | | | US | TBC | 18/10/02 | Application |
| | | | DMXAA 1 | Compounds having anti-tumor & antibacterial properties | 019/0003 - D Young & Co. | AT |
| BE | EP0278176 | 22/12/87 | | | | Granted |
| CH | EP0278176 | 22/12/87 | | | | Granted |
| DE | P3789299.1 | 22/12/87 | | | | Granted |
| ES | EP0278176 | 22/12/87 | | | | Granted |
| FR | EP0278176 | 22/12/87 | | | | Granted |
| GR | 3012092 | 22/12/87 | | | | Granted |
| HK | 1008801 | 10/12/97 | | | | Granted |
| IT | EP0278176 | 22/12/87 | | | | Granted |
| JP | 325109/87 | 22/12/87 | | | | Granted |
| LU | EP0278176 | 22/12/87 | | | | Granted |
| NL | EP0278176 | 22/12/87 | | | | Granted |
| SE | EP0278176 | 22/12/87 | | | | Granted |
| UK | EP0278176 | 22/12/87 | | | | Granted |
| US | 07/912,466 (US5281620) | 13/7/92 | | | | Granted |

CDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|---------|---------------------------------------|-----------------------------|-----------|--|--------------------|------------------------------|
| DMXAA 2 | Cancer Therapy | 019/0003 - D Young & Co. | NZ PCT | 336259 PCT/NZ00/00098 (WO00/76597) | 14/6/99 14/6/00 | Nationals Priority PCT |
| | | | EP | 942571.1 | 8/1/02 | Application |
| | | | JP | 01-502830 | 14/12/01 | Application |
| | | | NZ | 516564 | 11/1/02 | Application |
| | | | US | 10/014887 | 11/12/01 | Application |
| DMXAA 3 | Combination therapy for cancer | 019/0003 - D Young & Co. | NZ | NZ503199 | 3/3/00 | Nationals |
| | | | EP | 232871/00 | 1/8/00 | Priority |
| | | | US | 09/774,002 | 31/1/01 | Application |
| | | | EP | 01307370.5 | 30/8/01 | Application |
| DMXAA 4 | Cancer Therapy by combination therapy | 019/0003 - D Young & Co. | NZ | NZ 506060 | 28/7/00 | PCT |
| | | | PCT | PCT/NZ01/00154 (WO02/09700) | 22/7/01 | Priority PCT |
| DMXAA 5 | Anticancer compounds | 019/0003 - D Young & Co. | UK | 01212851.1 | 3/9/01 | Priority |
| | | | PCT | PCT/GB02/004025 | 3/9/02 | PCT |
| DMXAA 6 | Combination with NSAIDs | 019/0003 - D Young & Co. | UK | 0206839.3 | 22/3/02 | Priority |

CDGP/005/0012.A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|----------|--|------------------------------|-----------|-----------------------------|-------------|----------------------|
| Caket 1 | Materials & Methods relating to the expression of genes - Fusagene | 660/0005 - Newburn Ellis | UK | 9810999.4 | 21/5/98 | Nationals |
| | | | PCT | PCT/GB99/01609 | 21/5/99 | Priority Application |
| | | | AU | 40508/00 | 21/5/99 | Application |
| | | | CA | 2333144 | 27/12/00 | Application |
| | | | CN | 99808292.9 | 5/1/01 | Application |
| | | | EP | 99923745.6 | 31/5/99 | Application |
| | | | HK | 01103431.0 | 17/5/01 | Application |
| | | | INDIA | IN/PCT/2000/00627 | 12/12/00 | Application |
| | | | INDONESIA | W-20002666 | 20/12/00 | Application |
| | | | JP | 2000-549741 | 21/11/00 | Application |
| | | | KR | TBC | 21/11/00 | Application |
| | | | NZ | 508863 | 14/12/00 | Application |
| | | | SG | 200006708-2 | 21/11/00 | Application |
| | | | US | 09/700731 | 20/11/00 | Application |
| Glover 1 | Inhibiting Gene Expression (RNAi) | 047/0005 - Kilburn & Stirode | UK | GB 9927444.1 | 19/11/99 | Nationals |
| | | | PCT | PCT/GB00/04404 (WO01/36646) | 17/11/00 | Priority Application |
| | | | AU | 14065/01 | 23/5/02 | Application |
| | | | CA | TBC | TBC | Application |
| | | | EP | 00976188.3 | 17/11/00 | Application |
| | | | IL | 149666 | 14/5/02 | Application |
| | | | JP | 2001-538524 | 20/5/02 | Application |
| | | | MX | PA/a/2002/005013 | 17/5/02 | Application |
| | | | NO | 2002 2339 | TBC | Application |
| | | | NZ | 519325 | 31/5/02 | Application |
| | | | PL | TBC | 17/5/02 | Application |
| | | | SG | 200203380-1 | 12/6/02 | Application |
| | | | US | 10/150426 | 17/5/02 | Application |
| | | | ZA | 2002/3816 | 14/5/02 | Application |

CDGP/005/0012 A

| PROJECT | PATENT TITLE | CRV FILE REP. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|------------|--|-----------------------------|---|---|--|---|
| Graham 6 | Chemokine and uses thereof | 009/0008 - Mewburn Ellis | UK | 0207624.8 | 02/04/02 | Priority Priority PCT |
| Guldberg 1 | Materials and methods relating to nucleic acid amplification and profiling | 023/0004 - Mewburn Ellis | UK UK PCT | 0025913.5 0107547.2 PCT/GB01/04707 (WO02/34942) | 23/10/00 26/3/01 23/10/01 | Priority Priority Application |
| Hadfield 1 | Materials & methods for synthesising stilbenes | 010/0022 - Mewburn Ellis | UK PCT | 0031263.7 PCT/GB01/05534 | 21/12/00 14/12/01 | PCT Priority Application |
| Hadfield 2 | Substituted Stilbenes & their reactions | 010/0023 - Mewburn Ellis | UK UK PCT | 0031262.9 0100295.5 PCT/GB01/05702 | 21/12/00 5/1/01 20/12/01 | PCT Priority Priority Application |
| Jackson 2 | Anti-Cancer Compounds CU300919 Series of Compounds | 008/0022 - JA Kemp & Co | UK PCT AU CA EP JP US | GB 9904275.6 PCT/GB00/00655 (WO00/50417) 26838/00 2364708 00905212.7 2000-60098 09/914.010 | 24/2/99 24/2/00 31/8/01 21/8/01 16/8/01 24/8/01 19/10/01 | Priority Application Application Application Application Application |

CDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|----------|---|-----------------------------|---------|--------------------------------|-------------|-------------------|
| Luskey 3 | Determination of Cellular Growth Abnormally | 047/0007 - Newburn Ellis | UK | 972217.8 | 21/10/97 | Nationals |
| | | | UK | 9724134.3 | 14/11/97 | Priority |
| | | | UK | 9804156.9 | 26/2/98 | Priority |
| | | | UK | 9810560.4 | 15/5/98 | Priority |
| | | | UK | 9817075.6 | 5/8/98 | Priority |
| | | | PCT | PCT/GB98/03153 (WO99/21014) | 21/10/98 | Published 29/4/99 |
| | | | AU | 9895502 | 21/10/98 | Application |
| | | | CA | 2305872 | 21/10/98 | Application |
| | | | EP | 98949123.8 | 21/10/98 | Application |
| | | | JP | 11-523482 | 21/10/98 | Application |
| | | | NZ | 508996 | 21/10/98 | Granted |
| | | | UK | 2332515B | 21/10/98 | Granted |
| | | | US | 60/071245 | 22/12/97 | Provisional |
| | | | US | 60/086885 | 27/5/98 | Provisional |
| | | | US | 60/095966 | 16/10/01 | Provisional |
| | | | US | 09/175947 (6303323B1) | 21/10/98 | Granted |
| | | | US | 09/922652 | 8/7/01 | Divisional |

| PROJECT | MARK | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|------------|------|-----------------------------|---------|------------------------|-------------|----------|
| Marshall 2 | | 008/0025 - Newburn Ellis | UK | 0106641.4 | 16/3/01 | PCT |
| | | | PCT | PCT/GB02/01282 | 18/3/02 | Priority |

CDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRY FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|------------|---|--------------------------|----------------------------|--|--------------------|---|
| Minuett 1 | Materials and methods relating to the treatment of leukaemias | 027/0007 - Mewburn Ellis | UK PCT | 00072173 PCT/GB01/01274 | 24/3/00 22/3/01 | PCT Priority PCT |
| Nettle 6 | Therapeutic Acridone and Acridine Compounds | 008/0029 - Mewburn Ellis | US PCT | US 60/216624 PCT/GB01/03046 (WO02/08193) | 7/7/00 6/7/01 | Priority Application |
| Nettle 7 | Therapeutic Acridone and Acridine Compounds | 008/0039 - Mewburn Ellis | US | 60/347899 | 5/1/02 | Priority Priority Priority |
| Nettle 8 | Crystal Structure of C-Quadruplex | 008/0042 - Mewburn Ellis | UK | 02076230 | | Nationals |
| Pellicci 1 | Materials and methods relating to the effects of P66 expression | 027/0006 - Mewburn Ellis | UK PCT | 9906515.3 PCT/GB00/01079 (WO00/56886) | 22/3/99 22/2/00 | Priority PCT |
| | | | AU CA EP JP US | 0033124 2367464 00911131.1 2000-606745 09/937182 | 22/3/00 | Application Application Application Application Application |

CDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|------------|--|-----------------------|----------|-----------------------------|-------------------|----------------------|
| Plasterk 1 | Vectors and Methods for Providing Cells with Additional Nucleic Acid Material Integrated in the Genome of Said Cells | 037/0010 - Verelugde | EP | EP96200298.6 | 9/2/96 | Nationals |
| | | | PCT | PCT/NL97/00040 (WO97/29202) | 7/2/97 | Priority Application |
| | | | EP | 97902729.9 | 9/2/98 | Application |
| | | | AU | 16746/97 | 23/7/98 | Application |
| | | | CA | 2244812 | 31/7/98 | Application |
| | | | JP | 9-528410 | 7/8/98 | Application |
| | | | US | 08/909786 | 12/8/97 | Withdrawn |
| | | | US(CIP) | 09/317062 - 6,051,430 | 12/8/97 | Granted |
| | | | US | 09/117985 | 7/8/98 | Withdrawn |
| | | | US (CIP) | 09/731289 | 6/12/00 | Application |
| Plasterk 2 | Vectors and Methods for Providing Cells with Additional Nucleic Acid Material Integrated in the Genome of Said Cells | 037/0010 - Verelugde | PCT | PCT/NL98/00456 (WO99/07871) | 11/8/98 | Nationals |
| | | | AU | 87528/98 | 17/5/99 & 30/6/99 | Application |
| | | | CA | 2301198 | 17/5/99 | Application |
| | | | EP | 98939015.8 | 30/6/99 | Application |
| | | | JP | TBC | TBC | Application |
| | | | MX | 1495 | 11/2/00 | Application |
| | | | NZ | 502894 | 16/2/00 | Application |
| | | | US | 09/502624 | 11/2/00 | Application |

CDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|-------------|---|--|-----------------------------|--|---|--|
| Scheilens I | BCRP | 937/0016 - Nederlandsch Octroobureau | NL NL PCT EP US | 1012066 1012481 PCT/NL00/00331 009317207 09/988285 | 17/5/99 30/6/99 17/5/00 TBC TBC | Nationals Priority Priority Application Application Application |
| Shankhani I | Material and methods relating to the increase of protein activity | 078/0003 - Newburn Ellis | UK PCT | 0015426.0 PCT/GB01/02810 | 24/6/00 25/6/01 | Priority Application PCT |
| Shankhani 3 | Multimeric Proteins | 078/0008 - JA Kemp & Co | UK | 0125093.5 | 18/10/01 | Priority Priority Priority |
| Spitts I | Stat 5 materials and methods relating to the production and maintenance of cell lines | 037/0017 - Newburn Ellis | UK UK UK | 0130223.1 0206085.1 0206086.1 | 18/12/01 14/3/02 14/3/02 | Priority Priority Priority |

CDGP/005 / 0012 A

STATUS

Nationals

APPLICATION/PATENT FILING DATE

NO.

COUNTRY

CHY FILE REF. & AGENT
0710004 - Wilson Gunn Skerratt

PATENT TITLE

Benzothiazole Compounds for Use in Therapy 2-aryl benzothiazole compounds
CIN1126

PROJECT
Stevens I

| CHY FILE REF. & AGENT | NO. | COUNTRY | APPLICATION/PATENT FILING DATE | STATUS |
|-----------------------|---------|---------|--------------------------------|----------------------|
| GB 9317949.7 | 28/8/93 | | 28/8/93 | Priority Application |
| PCT/GB94/01883 | 30/8/94 | | 30/8/94 | Granted |
| (W/O95/06469) | 30/8/94 | | 30/8/94 | Granted |
| 182077 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 69419517 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| ES213357113 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 0721336 | 30/8/94 | | 30/8/94 | Granted |
| 690577 | 30/8/94 | | 30/8/94 | Application |
| 2100508 | 30/8/94 | | 30/8/94 | Application |
| 5080011995 | 28/2/96 | | 28/2/96 | Granted |
| 5874431 | | | | |

PORTUGAL
SE
UK
AU
CA
JP
US

CO

00000012 A

| PROJECT | PATENT TITLE | CRY FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|-----------|---|---------------------------------|---------|-----------------------------|-------------|----------------------|
| Stevens 2 | Benzazole Compounds 2-Arylbenzazole Compounds | 071/0005 - Wilson Gunn Skerrett | UK | GB 9503946.7 | 28/2/95 | Nationals |
| | | | PCT | PCT/GB96/00440 | 28/2/96 | Priority Application |
| | | | EP | 96904181.3 | 28/2/96 | Application |
| | | | AU | 711052 | 28/2/96 | Granted |
| | | | CA | 2213737 | 28/2/96 | Application |
| | | | JP | 526096/1996 | 28/2/96 | Application |
| US | 6034246 | 28/2/97 | Granted | | | |
| Stevens 4 | 2 Arylbenzazole Compounds | 071/0007 - Wilson Gunn Skerrett | UK | GB 9919673.5 | 20/8/99 | Nationals |
| | | | PCT | PCT/GB00/03210 (WO01/14354) | 21/8/00 | Priority Application |
| Stevens 5 | Therapeutic Polycyclic Compounds | 071/0008 - Mewburn Ellis | AU | 67085/00 | 21/8/00 | Application |
| | | | CA | 2382406 | 21/8/00 | Application |
| | | | EP | 00954726.6 | 21/8/00 | Application |
| | | | JP | 51844/2001 | 19/2/02 | Application |
| | | | US | 10/069018 | 20/2/02 | Application |
| Stevens 6 | Therapeutic Compounds | 071/0009 - Mewburn Ellis | US | US 60/239267 | 12/10/00 | PCT |
| | | | PCT | PCT/GB01/04557 | 12/10/01 | Priority Application |
| Stevens 6 | Therapeutic Compounds | 071/0009 - Mewburn Ellis | UK | 116594.3 | 6/7/01 | PCT |
| | | | PCT | PCT/GB02/003097 | 5/7/02 | Priority Application |

CDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRV FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|-------------|--|-----------------------------|-------------|------------------------|-------------|----------------------|
| Stevenson 1 | Improvements in or relating to immune response modification | 078/0005 - Mewburn Ellis | UK | 9220808.1 | 2/10/92 | Nationals |
| | | | PCT | PCT/GB93/02054 | 4/10/93 | Priority Application |
| | | | AU | 48324/93 - 685399 | 4/10/93 | Granted |
| | | | CA | 2,145,064 | 4/9/93 | Application |
| | | | EP | 93921048.0 | 4/10/93 | Application |
| | | | JP | 5088591994 | 4/10/93 | Application |
| US (CIP) | 08/896,535 | 18/7/97 | Application | | | |
| Stevenson 2 | Materials and methods relating to immune Responses | 078/0006 - Mewburn Ellis | UK | 0009470.6 | 17/4/00 | Nationals |
| | | | PCT | PCT/GB01/01719 | 17/4/01 | Priority Application |
| | | | EP | (WO01/79510) | 16/10/02 | Application |
| | | | JP | TBC | 16/10/02 | Application |
| US | TBC | 16/10/02 | Application | | | |
| Stevenson 3 | Materials and methods relating to fusion of proteins for inducing on Immune Response | 078/0009 - Mewburn Ellis | UK | 0028319.2 | 20/11/00 | PCT |
| | | | PCT | PCT/GB01/05142 | 20/11/01 | Priority Application |
| | | | | (WO02/40513) | | |
| Stevenson 4 | Materials and methods relating to the treatment of lymphoma | 078/0009 - Mewburn Ellis | UK | 0203395.7 | 7/3/02 | Priority |

CIDGP/005 / 0012 A

| PROJECT | PATENT TITLE | CRY FILE REF. & AGENT | COUNTRY | APPLICATION/PATENT NO. | FILING DATE | STATUS |
|-----------|---|-----------------------------|---------|---|--------------------|-------------------------|
| Valant 1 | Materials and methods for modulating T-cell activity | 037/0011 - Mewburn Ellis | UK | 0127602.1 | 16/11/01 | Priority |
| Workman 1 | Indole-3 Acetic Acid Derivatives | 011/0002 - Mewburn Ellis | UK | 0016162.0 PCT/GB01/02872 (WO02/02110) | 30/6/00 30/6/01 | Priority Application |
| Workman 2 | Therapeutic compounds and their uses in therapy (HSP90) | 008/0034 - Mewburn Ellis | UK | 0130733.9 | 21/12/01 | Priority |
| Workman 3 | Assay, Methods and Means | 008/0034 - Mewburn Ellis | UK | 0202871.0 | 12/7/02 | Priority |

CDCP/005 / 0012 A

IN WITNESS WHEREOF this Assignment has been executed as a deed by the parties' duly authorised representatives and delivered on the day and year first before written

EXECUTED as a DEED by)
CANCER RESEARCH)
TECHNOLOGY LIMITED acting by:)

KANPAL S. KANAR
Director

CLIVE STANWAY
Director/Secretary



Clive Stanway

EXECUTED as a DEED by)
CANCER RESEARCH VENTURES)
LIMITED acting by:)

KEITH BLUNDY
Director

GEORGE PICKERING
Director/Secretary



C. P. G. Pickering